NASDAQ:ICCC

ImmuCell (ICCC) Stock Price, News & Analysis

ImmuCell logo
$11.33 -0.09 (-0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$11.22 -0.11 (-0.97%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About ImmuCell Stock (NASDAQ:ICCC)

Advanced

Key Stats

Today's Range
$10.79
▼
$11.73
50-Day Range
$9.58
▼
$11.42
52-Week Range
$4.52
▼
$12.10
Volume
18,535 shs
Average Volume
12,701 shs
Market Capitalization
$102.99 million
P/E Ratio
57.10
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

ImmuCell is an animal health company focused on products for cattle. It develops, manufactures and markets products intended to support the health of dairy and beef herds.

Its best-known product line, First Defense, consists of oral antibody products given to newborn calves to help protect against common causes of scours, a form of calf diarrhea. The products are designed to provide targeted antibodies during the early stages of life.

ImmuCell has also developed Re-Tain, a non-antibiotic product for subclinical mastitis in dairy cows. The company is based in Portland, Maine, and has a history of developing antibody-based products for animal health.

AI Generated. May Contain Errors.

ImmuCell Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
23rd Percentile Overall Score

ICCC MarketRank™: 
1.145861059355 of 5 stars

ImmuCell scored higher than 23% of companies evaluated by MarketBeat, and ranked 792nd out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    ImmuCell has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    ImmuCell has only been the subject of 1 research reports in the past 90 days.

  • Read more about ImmuCell's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of ImmuCell is 57.10, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.44.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of ImmuCell is 57.10, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.76.

  • Price to Book Value per Share Ratio

    ImmuCell has a P/B Ratio of 3.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.17% of the float of ImmuCell has been sold short.
  • Short Interest Ratio / Days to Cover

    ImmuCell has a short interest ratio ("days to cover") of 2.79, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in ImmuCell has recently decreased by 18.76%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    ImmuCell does not currently pay a dividend.

  • Dividend Growth

    ImmuCell does not have a long track record of dividend growth.

  • News Sentiment

    ImmuCell has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for ImmuCell this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, ImmuCell insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    5.70% of the stock of ImmuCell is held by insiders.

  • Percentage Held by Institutions

    13.47% of the stock of ImmuCell is held by institutions.

  • Read more about ImmuCell's insider trading history.
Receive ICCC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ImmuCell and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ICCC Stock News Headlines

ImmuCell (ICCC) Q3 2026 Earnings Call Transcript
Top Trader Reveals Stunning Black Friday Deal
Others paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.tc pixel
ImmuCell Corporation (ICCC) Q3 2026 Earnings Call Transcript
ImmuCell Q3 Preliminary Sales Rise
See More Headlines

ICCC Stock Analysis - Frequently Asked Questions

ImmuCell's stock was trading at $6.15 at the beginning of 2026. Since then, ICCC stock has increased by 84.2% and is now trading at $11.33.

ImmuCell Corporation (NASDAQ:ICCC) issued its earnings results on Thursday, November, 12th. The biotechnology company reported $0.10 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.05. The biotechnology company earned $8.04 million during the quarter, compared to the consensus estimate of $5.40 million. ImmuCell had a trailing twelve-month return on equity of 6.25% and a net margin of 5.66%.
Read the conference call transcript
.

ImmuCell's top institutional investors include Mink Brook Asset Management LLC (2.24%) and State Street Corp (0.15%). Insiders that own company stock include David Scott Tomsche and Boekhorst Paul Francis Oliv Te.
View institutional ownership trends
.

Shares of ICCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuCell investors own include CRISPR Therapeutics (CRSP), MARA (MARA), Novavax (NVAX), Neurocrine Biosciences (NBIX), Aqua Metals (AQMS), Boxlight (BOXL) and Cleanspark (CLSK).

Company Calendar

Last Earnings
11/12/2026
Today
11/17/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NASDAQ:ICCC
CIK
811641
Employees
73
Year Founded
1982

Profitability

EPS (Trailing Twelve Months)
$0.20
Trailing P/E Ratio
57.10
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$1.04 million
Net Margins
5.66%
Pretax Margin
5.79%
Return on Equity
6.25%
Return on Assets
4.15%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
4.61
Quick Ratio
2.50

Sales & Book Value

Annual Sales
$27.64 million
Price / Sales
3.73
Cash Flow
$0.19 per share
Price / Cash Flow
59.23
Book Value
$3.61 per share
Price / Book
3.14

Miscellaneous

Outstanding Shares
9,090,000
Free Float
8,573,000
Market Cap
$102.99 million
Optionable
Not Optionable
Beta
0.61

Social Links

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

This page (NASDAQ:ICCC) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners